Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Government agencies communicate via .gov.sg websites (e.g. go.gov.sg/open). Trusted websites
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

Agency for Care Effectiveness
Drug guidance

Brentuximab vedotin for treating T-cell lymphoma

Condition

Blood and Immune System

Cancer

1 June 2026

Published on 12 Jul 2022
Last Updated on 1 Jun 2026

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has recommended:

  • Brentuximab vedotin 50 mg powder for infusion in line with its registered indications for treating:

    • Previously untreated CD30-positive peripheral T-cell lymphoma when used with cyclophosphamide, doxorubicin and prednisone;

    • Relapsed or refractory systemic anaplastic large cell lymphoma; and

    • CD30-positive cutaneous T-cell lymphoma, after at least one prior systemic therapy.

Funding status

Brentuximab vedotin 50 mg powder for infusion is recommended for inclusion on the MOH Medication Assistance Fund (MAF) for the abovementioned indications with effect from 1 September 2022.

Clinical indications, subsidy class and MediShield Life claims eligibility are provided in the Annex.

Brentuximab vedotin for treating T-cell lymphoma (1 Jun 26) [PDF, 133 KB]

PES Brentuximab for T-cell lymphoma (Published 12 July 2022) [PDF, 96 KB]

Back to top